The purpose is to review recent advances in molecular imaging of neuroendocrine tumors (NETs), discuss unresolved issues, and review how these advances are affecting clinical management.
INTRODUCTION

WHY IMAGING IS IMPORTANT IN NEUROENDOCRINE TUMORS AND FREQUENTLY DIFFICULT
Accurate tumor imaging is essential to planning the approach in all phases of management of patients with NETs. First, surgical resection remains the only curative procedure and thus should be carried out whenever it can be safely undertaken and has a high promise of a curative result [ 
KEY POINTS
There have been numerous advances in molecular imaging of NETs over the last few years.
Molecular imaging in NET patients currently consists of SRS (using 111 In-DTPA-peptide SPECT/CT, 68 Ga-DOTApeptide PET/CT; approved in the USA/many countries); 18 F-FDG PET/CT; 18 F-FDOPA PET/CT; with less frequent general use of 125 I-MIBG or 11 C-5-HTP PET/CT. 68 Ga-DOTA-peptide PET/CT is rapidly replacing 111 In-DTPA-peptide SPECT/CT because of its greater resolution resulting in greater sensitivity and changes in patient management.
Recent studies have compared these different modalities, helping to define their place in management, which has resulted in some being complementary ( 68 Ga-DOTA-peptide PET/CT/ 18 F-FDG) and also leading to some controversies and unresolved issues.
Newer, novel ligands with different linkers and radiolabels are being described including somatostatin receptor antagonists, which show enhanced imaging.
Ligands for other receptors (CCK, GLP-1, GIP, bombesin, chemokines, integrins) are reported, that also show promise for imaging NETs and other tumors. or treatment modalities directed at liver-predominant disease (embolization, chemoembolization, radioembolization), all of which have been successful in various series [18, 19] . Tumor imaging has been particularly difficult in a number of subgroups of patients with NETs. Patients with functional pNETs characteristically present with symptoms of the hormone-excess state [5, 6] with small primary tumors (<1 cm), which are frequently missed by conventional imaging studies. The success of cross-sectional imaging studies is very much affected by tumor size: detecting 10-30% of NETs less than 1-1.5 cm, whereas they detect more than 80% of those more than 3 cm [3,5,12 & ]. Measurements of hormonal gradients is more sensitive [12 & ,20-22] , but is usually performed with angiography (insulinomas, gastrinomas), is invasive and uncommonly performed nowadays, except to localize insulinomas in specialized centers in the uncommon patient when all other studies are negative, or in patients with MEN1 [3,12 & ]. Patients with GI-NETs (carcinoids) and carcinoid syndrome have liver metastases in more than 95% of cases at the time of presentation [3] . In some of these patients, as well as patients presenting with metastatic nonfunctional NETs, the primary tumor can be small and difficult to localize, but its localization is important in selecting the proper antitumor treatment [15, [23] [24] [25] [26] . Lastly, both malignant pNETs as well as GI-NETs frequently metastasize to adjacent lymph nodes, which are not seen on cross-sectional imaging and which can be difficult to localize at surgery [5, 17, 27] . Each of these points argue for the need for more sensitive imaging modalities in patients with NETs.
MOLECULAR IMAGING OF NEUROENDOCRINE TUMORS
General aspects
There are a number of molecular imaging approaches for NETs that are increasingly being used. These include somatostatin receptor scintigraphy (SRS) using ligands that are targeted to somatostatin receptors (primarily sst2) overexpressed by NETs [7 && ,28]. This method is now approved in many countries, including the USA and utilizes primarily 111 In-DPTA-peptides, with single-photon emission computed tomography (SPECT)/CT imaging or using 68 Ga-DOTA(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)-peptides with PET combined with CT imaging (PET/CT) or MRI (PET/MRI) [ Initially, beginning in the 1990s, the most widely used approach was SRS with 111 In-DPTA-labeledsomatostatin agonist analogues, which had high affinity primarily for the somatostatin receptor subtype sst2 [8, 9, 35] . For well differentiated NETs, 80-100% express at least one of the five somatostatin receptor subtypes (sst1-5), with the most frequent being sst2 (>80%).This approach has greater sensitivity than conventional imaging studies, generally ranging from 60 to 90% for both pNETs and GI-NETs [8, 9, [35] [36] [37] . It has proven especially useful for allowing whole-body imaging at one time and for detecting distant metastases, whereby its use resulted in management changes in 25-50% of cases [35, 38, 39] . This approach is limited by the size of NET (identify < 50% < 1 cm) [8, 40] and by the degree of differentiation of the NET, because poorly differentiated CCK, cholecystokinin; CT, computed tomography; DTPA, diethylenetriamine penta-acetic acid; FDG, fluoro-deoxyglucose; Ga, gallium; GIP, gastric inhibitory polpeptide; NET, neuroendocrine tumors; SPECT, single-photon emission computed tomography.
tumors frequently either do not express somatostatin receptors or do so only at low densities [8, 35, 36] . However, this approach allows an assessment of magnitude of uptake by the tumor and establishes the presence of somatostatin receptors in the NET, which can be used to plan therapy with other radiolabeled somatostatin analogues (
Lu-labeled analogues), using peptide receptor radionuclide radiotherapy (PRRT) [8, 35, 36] .
PRRT will not be generally discussed in this review, however, it is receiving much attention as a therapeutic, targeted approach for patients with advanced NETs, and thus plays a role in the utilization of SRS, to assess whether this approach might be considered, by establishing the presence of somato- Lu-DOTA-Tyr3-Octreotate (DOTATATE) in patients with unresectable advanced ileal NETs has been reported in preliminary communications to be effective with an acceptable safety profile. Therefore, the availability of PRRT in the future will be a major factor in determining the use of SRS.
Over the last 3-5 years there have been considerable advances in molecular imaging of NETs, both in describing new approaches, new ligands, as well as comparison of different methods and studies leading to a better definition of their potential place in standard medical practice (Table 1) . In some cases, this had led to controversies and unresolved issues (Table 2) and changes in clinical management. These will be briefly reviewed in the following sections.
Rise of 68 Ga-DOTA-peptide PET/CT imaging Molecular imaging with 68 Ga-DOTA-labeled somatostatin analogues has a number of advantages over imaging with 111 In-diethylenetriamine penta-acetic acid (DTPA)-peptide SPECT/CT and is now becoming the standard, which is recommended in most current guidelines and is approved in many countries, including recently in the USA [ In-DTPA-peptides/ SPECT); has a shorter half-life of 68 min, allowing rapid scanning (1-3 h postinjection vs. 24-48 h for 111 In); it is produced from a generator rather than a cyclotron; its effective dose is less than one-half of that using 111 In-DTPA-peptides and the tissue contrast is better with PET/CT than with SPECT/CT imaging [ [55, 56] , medullary thyroid cancer [50] , pheochromocytomas [56, 57] , and ectopic Cushing's syndrome [58] . Furthermore, a meta-analysis in 2012 [59] involving 16 studies (567 NET patients including patients with thoracic NETs) reported a sensitivity of 93% on a per-lesion basis (91% per-patient basis) with excellent specificity. A more recent meta-analysis [48 && ] summarizing 42 studies supported the superiority of 68 Ga-DOTA PET/CT over conventional imaging or 111 In-DTPA SPECT/CT demonstrating a high sensitivity (90%), specificity (91%), and its safety. Occasional false negatives were observed and occurred primarily in poorly differentiated NETs or insulinomas that have no or low somatostatin receptor sst2 expression and with small lesions (<0.7 cm) [59] . During interpretation of the 68 Ga-DOTA-peptide PET/CT images, numerous studies have pointed out false positives can occur because of uptake in the uncinate process of the pancreas, the adrenal gland, or because of high somatostatin receptor expression in the spleen and splenosis, with inflammatory processes, or with increased osteoblastic activity [60, 61] . The use of Ga-DOTA-peptides by NETs strongly correlates with the tumor expression of sst2 [50, 69, 70] . A number of recent studies [53, [71] [72] [73] [74] have reported that the maximum standardized uptake value (SUV/max) of 68 Ga-DOTA-peptide PET/ CT imaging of NETs has important prognostic and predictive value. In well differentiated NETs, it was an independent predictor of progression-free survival (PFS) [53, 74] . In another study [71] , a cutoff value of 16.4 for Ga-DOTA-peptide PET/CT has also been reported to be predictive in patients with advanced NETs regarding their response to octreotide therapy with a SUV/max more than 29.4 associated with a longer PFS [72] . In patients with well differentiated G1/G2 pNETs [73] , a SUV/max more than 37.8 on 68 Ga-DOTA-peptide PET/CT was an independent predictor of PFS.
Three different 68 Ga-linker somatostatin-labeled analogues have been used in different studies, including 68 Ga-DOTATATE (the most commonly used), 68 Ga-DOTATOC, and 68 Ga-DOTANOC [47, 50, 75] . These differ in their affinities for the different somatostatin receptor subtypes (sst1-5), but all have high affinity for sst2. Each of these performs better than SRS with 111 In-DTPA-peptide SPECT/CT [32, 47, 75] . They have been directly compared in relatively few studies with one suggesting uptake was better with 68 Ga-DOTATATE [76] and a second reported the sst2,3,5-specific 68 Ga-DOTANOC detected more lesions [75] . Reviews of all studies comparing these different ligands concluded that overall there seemed to be no or little major difference in their performance [32, 47] . Ga-DOTA-peptide PET/CT either alone or together [74, 77, 79, 80] . In general, these studies support the conclusion that 68 Ga-DOTA-peptide PET/CT demonstrated superior imaging in well differentiated G1/G2 NETs compared with 18 F-FDG PET/CT, whereas 18 F-FDG PET/CT demonstrates higher uptake in poorly differentiated G3 NETs than 68 Ga-DOTA-peptide PET/CT [77, 79] . A similar pattern is seen with lung carcinoids with 68 Ga-DOTApeptide PET/CT being more sensitive than 18 F-FDG PET/CT for detecting typical carcinoids, whereas the reverse was true for atypical lung carcinoids [85 & ]. The presence of 18 F-FDG PET/CT in NETs has been shown to correlate strongly with high rate of progression and to have prognostic significance [77, 78, 81, 83, 84] . In one study, patients with a positive 18 F-FDG PET/CT with a SUV ratio of 2.5 or greater had a 4-year survival rate of 0% [81] . Furthermore, in a number of studies, some patients with G1/G2 tumors had positive 18 F-FDG PET/CT uptake which had important predictive value [33, 77, 82] . A number of studies have concluded that the results of Ga-DOTApeptide PET/CT in patients with NETs are complementary in providing different information that is clinically relevant [77, 79, 80] . In one study, their combined impact was to change the therapeutic decision in 59% of the patients [79] .
Comparison of
In well differentiated NETs, the SUV/max for 68 Ga-DOTA PET/CT is superior to that for 18 F-FDG PET/CT as an independent prognostic factor for PFS [53] .
SRS with 111
In-DPTA SPECT/CT has also been compared with 18 F-FDG PET/CT in studies [81, 82, 86] . Similar, although less dramatic results compared with those seen with the comparison of 68 Ga-DOTA PET/CT and 18 F-FDG PET/CT reviewed above, were obtained. SRS with 111 In-DPTA-peptide SPECT/CT had greater sensitivity for well differentiated NETs than 18 F-FDG PET/CT, and the reverse was true for poorly differentiated NETs [82] . The sensitivity of 111 In-DPTA-peptide SPECT/CT and 18 F-FDG PET/CT were very much affected by the tumor grade, being 79 vs. 52% for grade 1, 85 vs. 86% for grade 2, and 57 vs. 100% for grade 3 [82] . 111 In-DPTA-peptide SPECT/CT negativity and 18 F-FDG PET/CT positivity correlate with early tumor progression [86] , and 18 F-FDG PET/CT positivity [78, 86] correlated with shortened PFS and overall survival.
Comparison of 68
Ga-DOTA PET/CT and 18 F-FDOPA PET/CT 18 F-FDOPA PET/CT takes advantage of the fact that NETs take up and decarboxylate amine precursors by assessing the ability of the tumor cells to be taken up by a neutral amino acid transporter (LAT1/4F2hc) [87] . In contrast, 68 Ga-DOTA-peptide PET/CT assesses NET somatostatin receptor expression; and therefore, these two imaging modalities assess different characteristics of NETs. A number of studies have recently compared these two radiolabeled peptides in patients with different NETs [56] . In patients with pheochromocytomas and paragangliomas, 68 Ga-DOTA-peptide PET/CT is more sensitive than 18F-FDOPA PET/CT in detecting head and neck paragangliomas, especially in patients with succinate dehydrogenase subunit b mutations [56] . 18 F-FDOPA PET/CT is reported to be a good modality for detecting medullary thyroid cancer, investigating hyperinsulinemic states, and is more sensitive than SRS with 111 In-DTPA SPECT/CT in detecting and staging carcinoid tumors, but not pNETs [8, 34, 87, 88] .
In one comparative study, 18 F-FDOPA PET/CT was less sensitive than 68 Ga-DOTA-peptide PET/CT in detecting NETs (70% pNETs) [89] .
Similar to 68 Ga-DOTA-peptide PET/CT, 18 F-FDOPA PET/CT is of limited value in localizing insulinomas [46, [90] [91] [92] . Carbidopa is an inhibitor of peripheral aromatic amino acid decarboxylase, and its administration has been shown to increase the sensitivity of 18 F-FDOPA PET/CT detection of insulinomas to 70% [93] . In another study [94] , carbidopa premedication increased the sensitivity of 18 F-FDOPA PET/CT to 90% for localizing NFpNETs, which was superior to the 68% seen with 111 In-DTPA SPECT/CT imaging.
Use of radiolabeled antagonists rather than agonists
Initially, only radiolabeled somatostatin receptor agonists were used for SRS/PRRT because it was assumed that cellular internalization of ligand by the tumor was essential for both imaging and for PRRT, because with numerous G protein-coupled receptors, peptide agonists but not antagonists are internalized [95, 96] . However, in preclinical studies in animals, 111 In-labeled sst2/sst3 peptide receptor antagonists showed superior binding in both amount and in retention time with cells expressing these receptors, than seen with 111 Inlabeled agonists [96] , even though the antagonists were not internalized. Analysis of the binding characteristics demonstrated the antagonist showed a 10 times higher number of binding sites than seen with the agonist [96] , possibly because it was interacting with predominately low-affinity receptor sites, whereas the agonist may have interacted with predominately high-affinity receptor states.
Subsequently, in a study of five patients with metastatic thyroid cancers or NETs [95] , a radiolabeled antagonist, 111 In-DOTA-BASS, showed higher tumor uptake and lower renal retention than the radiolabeled agonist, and imaged more lesions.
These promising results have been extended to the investigation of the relative value of radiolabeled somatostatin analogues that are agonists or antagonists, for their tumoricidal effects on sst2-containing tumor cells by PRRT [97] . In a preclinical study, the radiolabeled antagonist, 177 Lu-DOTA-JR11, demonstrated five times greater tumor cell-associated radioactivity than the agonist, 177 Lu-DOTA-octreotate, caused more double-stranded DNA breaks in the tumor, showed in biodistribution studies a four times greater radiation dose with the antagonist and in an in-vivo study, and resulted in a longer tumor growth delay. These promising results were extended recently to investigate the comparative effect of these two ligands for PRRT in four patients with advanced NETs [98] . 177 Lu-DOTA-JR11 delivered 1.7 to 10.6-fold higher tumor doses than 177 Lu-DOTATATE, and the tumor-kidney and tumor to bone marrow dose was 1.1-7.2 times higher. The radiolabeled antagonist caused a partial remission in 2/4 patients, stable disease in one patient and a mixed response in the fourth patient [98] . These results demonstrate that radiolabeled somatostatin receptor antagonists show promise of being superior agents to the currently widely used radiolabeled agonists, for both imaging and for PRRT.
Development of other radiolabeled ligands for imaging 68 Ga has a short half-life of 68 min, which can lead to logistic problems with many patients examined daily and it has a limited spatial resolution, which can be overcome by the use of 64 Cu (half-life À12.7 h), allowing once daily preparation for multiple uses, and it has lower positron energy than 68 Ga, which should translate into better spatial resolution [99] [100] [101] . In 14 patients with NETs, 64 Cu-DOTATATE imaging was investigated using both SPECT/CT and PET/CT [100] . Images of excellent quality with high spatial resolution were obtained and in 43% of patients additional lesions were found using PET/CT compared with SPECT/CT [100] . In a second study [99] , 64 Cu-DOTATATE PET/ CT was compared prospectively with 111 In-DTPAoctreotide in 112 patients with confirmed NETs. The diagnostic sensitivity of 64 Cu-DOTATATE PET/CT was 97/97%, which was significantly better than 111 In-DTPA-octreotide (87/87%) and with 64 Cu-DOTATATE PET/CT twice as many lesions were detected, including in 36% of patients in organs thought not involved by 111 In-DTPA-octreotide imaging [99] . A recent study [102 && ] reports a prospective, head-to-head comparison of 64 Cu-DOTA-TATE PET/CT and 68 Ga-DOTATATE PET/CT in 59 NET patients and found they had equal sensitivity on a per-patient basis, but 64 Cu-DOTATATE PET/CT identified significantly more lesions and its longer half-life made it easier to use in a clinical setting.
A preclinical study reports [103] excellent imaging of HEK-sst2 containing xenografts by two sst2-radiolabeled antagonists, 64 Cu and 68 Ga-NODAGA-LM3. The authors conclude that these ligands are promising candidates for imaging with favorable pharmacokinetics and high image contrast on PET/CT [103] .
Using somatostatin receptor overexpression to deliver cytotoxic doses of radiolabeled somatostatin receptor ligands (PRRT) has received the most attention using b-emitting isotopes ( 90 Y, 177 Lu); however, a significant number of patients do not show tumor shrinkage and new approaches are being considered. One approach is to use 213 Bi-DOTATOC, which allows targeted a-particle therapy [104] . In one study of seven patients refractory to 90 
Novel ligands and approaches
In addition to ligands for somatostatin receptors, a number of other molecular imaging probes are in development, which may prove to be useful not only in NETs, but also a wide group of other tumors. These include: radiolabeled GLP-1 receptor ligands [90,113 & ,114], which show particular promise in imaging insulinomas and adult nesidioblastosis; radiolabeled agonists interacting with the chemokine receptor, CXCR4, which is frequently overexpressed in proliferating and advanced tumors, including small cell lung cancer cells and NETs [16, 115] ; 68 Ga-DOTA-labeled cholecystokinin (CCK)2 receptor ligands for imaging medullary thyroid cancer and small cell lung cancer [116] [117] [118] ; radiolabeled bombesin receptor ligands (agonists/ antagonists; BB1, BB2,BB3 receptor), which can image a large range of tumors (prostate, colon, breast, central nervous system, NETs) [15,119 & ]; radiolabeled ligands which interact with vasoactive intestinal peptide-pituitary adenylate cyclase activating polypeptide receptors (VPAC1, VPAC2, PAC), which also can image a wide range of tumors [120 & ], and radiolabeled ligands interacting with the glucose-dependent insulinotropic polypeptide receptor, which is overexpressed by a number of tumors, including NETs and whose expression correlates with the proliferative index, whereas sst expression does not [121] [122] [123] [124] [125] [126] . A recent study demonstrated that a combination of gastric inhibitory polpeptide (GIP), somatostatin, and GLP-1 agonists identified all NETs, because at least one is overexpressed by all tumors and therefore it was proposed, triple-peptide receptor targeting (glucose-dependent insulinotropic polypeptide receptor, sst, glucagon-like peptide-1R) should be considered for enhanced sensitivity [121, 123] . An additional area of molecular imaging receiving increased attention is the targeting of tumor's angiogenesis, including NETs, which are vascular tumors, using increased expression of integrin receptors [127,128 & ,129-132] .
CONCLUSION
Molecular imaging by performing SRS (using 111 In-DTPA-peptide SPECT/CT or 68 Ga-DOTA-peptide PET/CT) is now an essential component in almost all steps in the management of patients with NETs.
Both are approved in the USA and many countries. However, numerous studies now demonstrate in many different types of NETs, that 68 Ga-DOTApeptide PET/CT is the preferred modality because of its greater sensitivity, excellent specificity, better resolution, and its use changes patient management in 20-70% of cases. Recent studies demonstrate that 68 Ga-DOTA-peptide PET/CT also has prognostic value and that it and 18 F-FDG PET/CT can be complementary. Recent studies have helped to define the role of 18 F-FDOPA PET/CT and reported novel ligands for SRS, which show promise, include antagonists, which show enhanced imaging of NETs. Furthermore, other molecular receptor ligands for imaging are being studied (CCK, GLP-1, GIP, chemokines, integrins, bombesin), which show promise in both NETs and other tumors.
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